Vivos therapeutics regains compliance with nasdaq listing requirements

Littleton, colo., jan. 20, 2023 (globe newswire) -- vivos therapeutics, inc. (“vivos” or the “company'') (nasdaq: vvos), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (osa) and snoring in adults, today announced that it has received a notice from the listing qualifications department of the nasdaq stock market (“nasdaq”) informing vivos it has regained compliance with the minimum bid price requirement for continued listing on the nasdaq under nasdaq listing rule 5550(a)(2).
VVOS Ratings Summary
VVOS Quant Ranking